{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T21:37:47Z","timestamp":1771537067133,"version":"3.50.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13195-017-0307-1","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T11:25:05Z","timestamp":1507202705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Gene suppression approaches to neurodegeneration"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0783-4430","authenticated-orcid":false,"given":"Rhia","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J.","family":"Tabrizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"key":"307_CR1","unstructured":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IONIS-HTTRx in Patients with Early Manifest Huntington's Disease. NCT02519036 . 2015."},{"key":"307_CR2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83\u201398.","journal-title":"Lancet Neurol."},{"key":"307_CR3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","volume":"12","author":"TM Miller","year":"2013","unstructured":"Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435\u201342.","journal-title":"Lancet Neurol."},{"key":"307_CR4","doi-asserted-by":"crossref","unstructured":"DeVos SL, Miller RL, Schoch KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9(374).","DOI":"10.1126\/scitranslmed.aag0481"},{"key":"307_CR5","doi-asserted-by":"crossref","unstructured":"Cole T, Paumier K, Zhao H, Weihofen A, Kordasiewicz H, Swayze E. Snca targeted antisense oligonucleotides mediate progression of pathological deposition in alpha synuclein rodent transmission models of Parkinson\u2019s disease. AAN Annual Meeting Poster Session VI. Vancouver: Vancouver Convention Centre; 2016. P6.239. http:\/\/www.abstractsonline.com\/pp8\/#!\/4046\/presentation\/6251 .","DOI":"10.1212\/WNL.86.16_supplement.P6.239"},{"key":"307_CR6","doi-asserted-by":"crossref","unstructured":"Zhao H, Cole T, Weihofen A, Swayze E, Kordasiewicz H. Antisense oligonucleotides to LRRK2 ameliorate alpha-synuclein pathology and behavioral deficit induced by pre-formed alpha-synuclein fibrils (I1.007). AAN Annual Meeting INS Data Blitz. Vancouver: Vancouver Convention Centre; 2016. http:\/\/www.abstractsonline.com\/pp8\/#!\/4046\/presentation\/8588 .","DOI":"10.1016\/j.omtn.2017.08.002"},{"key":"307_CR7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature22044","volume":"544","author":"DR Scoles","year":"2017","unstructured":"Scoles DR, Meera P, Schneider MD, et al. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature. 2017;544:362\u20136.","journal-title":"Nature."},{"key":"307_CR8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature22038","volume":"544","author":"LA Becker","year":"2017","unstructured":"Becker LA, Huang B, Bieri G, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367\u201371.","journal-title":"Nature."},{"key":"307_CR9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.drudis.2014.09.011","volume":"20","author":"BM Godinho","year":"2015","unstructured":"Godinho BM, Malhotra M, O'Driscoll CM, Cryan JF. Delivering a disease-modifying treatment for Huntington's disease. Drug Discov Today. 2015;20:50\u201364.","journal-title":"Drug Discov Today."},{"key":"307_CR10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","volume":"15","author":"M Ha","year":"2014","unstructured":"Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509\u201324.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"307_CR11","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1093\/hmg\/ddv442","volume":"25","author":"MS Keiser","year":"2016","unstructured":"Keiser MS, Kordasiewicz HB, McBride JL. Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia. Hum Mol Genet. 2016;25:R53\u201364.","journal-title":"Hum Mol Genet."},{"key":"307_CR12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/hum.2008.928","volume":"19","author":"AR Fougerolles de","year":"2008","unstructured":"de Fougerolles AR. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther. 2008;19:125\u201332.","journal-title":"Hum Gene Ther."},{"key":"307_CR13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/mt.2015.169","volume":"24","author":"RL Lecaros","year":"2016","unstructured":"Lecaros RL, Huang L, Lee TC, Hsu YC. Nanoparticle delivered VEGF-A siRNA enhances photodynamic therapy for head and neck cancer treatment. Mol Ther. 2016;24:106\u201316.","journal-title":"Mol Ther."},{"key":"307_CR14","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2012.08.014","volume":"150","author":"WF Lima","year":"2012","unstructured":"Lima WF, Prakash TP, Murray HM, et al. Single-stranded siRNAs activate RNAi in animals. Cell. 2012;150:883\u201394.","journal-title":"Cell."},{"key":"307_CR15","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2012.08.002","volume":"150","author":"D Yu","year":"2012","unstructured":"Yu D, Pendergraff H, Liu J, et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell. 2012;150:895\u2013908.","journal-title":"Cell."},{"key":"307_CR16","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","volume":"12","author":"E Rodriguez-Lebron","year":"2005","unstructured":"Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington's disease transgenic mice. Mol Ther. 2005;12:618\u201333.","journal-title":"Mol Ther."},{"key":"307_CR17","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1073\/pnas.0801775105","volume":"105","author":"JL McBride","year":"2008","unstructured":"McBride JL, Boudreau RL, Harper SQ, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A. 2008;105:5868\u201373.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"307_CR18","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/mt.2011.185","volume":"19","author":"RL Boudreau","year":"2011","unstructured":"Boudreau RL, Spengler RM, Davidson BL. Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol Ther. 2011;19:2169\u201377.","journal-title":"Mol Ther."},{"key":"307_CR19","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.bbrc.2005.02.024","volume":"329","author":"ZJ Chen","year":"2005","unstructured":"Chen ZJ, Kren BT, Wong PY, Low WC, Steer CJ. Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference. Biochem Biophys Res Commun. 2005;329:646\u201352.","journal-title":"Biochem Biophys Res Commun."},{"key":"307_CR20","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"SQ Harper","year":"2005","unstructured":"Harper SQ, Staber PD, He X, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A. 2005;102:5820\u20135.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"307_CR21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neures.2005.06.021","volume":"53","author":"YL Wang","year":"2005","unstructured":"Wang YL, Liu W, Wada E, Murata M, Wada K, Kanazawa I. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci Res. 2005;53:241\u20139.","journal-title":"Neurosci Res."},{"key":"307_CR22","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","volume":"104","author":"M DiFiglia","year":"2007","unstructured":"DiFiglia M, Sena-Esteves M, Chase K, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A. 2007;104:17204\u20139.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"307_CR23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bbrc.2006.02.141","volume":"343","author":"Y Machida","year":"2006","unstructured":"Machida Y, Okada T, Kurosawa M, Oyama F, Ozawa K, Nukina N. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem Biophys Res Commun. 2006;343:190\u20137.","journal-title":"Biochem Biophys Res Commun."},{"key":"307_CR24","doi-asserted-by":"crossref","first-page":"10238","DOI":"10.1073\/pnas.0802759105","volume":"105","author":"MD White","year":"2008","unstructured":"White MD, Farmer M, Mirabile I, Brandner S, Collinge J, Mallucci GR. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci U S A. 2008;105:10238\u201343.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"307_CR25","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87:493\u2013506.","journal-title":"Cell."},{"key":"307_CR26","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","volume":"17","author":"RL Boudreau","year":"2009","unstructured":"Boudreau RL, McBride JL, Martins I, et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther. 2009;17:1053\u201363.","journal-title":"Mol Ther."},{"key":"307_CR27","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","volume":"65","author":"V Drouet","year":"2009","unstructured":"Drouet V, Perrin V, Hassig R, et al. Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol. 2009;65:276\u201385.","journal-title":"Ann Neurol."},{"key":"307_CR28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.2013.200","volume":"25","author":"LM Stanek","year":"2014","unstructured":"Stanek LM, Sardi SP, Mastis B, et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. Hum Gene Ther. 2014;25:461\u201374.","journal-title":"Hum Gene Ther."},{"key":"307_CR29","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","volume":"19","author":"JL McBride","year":"2011","unstructured":"McBride JL, Pitzer MR, Boudreau RL, et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther. 2011;19:2152\u201362.","journal-title":"Mol Ther."},{"key":"307_CR30","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awr333","volume":"135","author":"R Grondin","year":"2012","unstructured":"Grondin R, Kaytor MD, Ai Y, et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain. 2012;135:1197\u2013209.","journal-title":"Brain."},{"key":"307_CR31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.expneurol.2011.11.020","volume":"233","author":"DK Stiles","year":"2012","unstructured":"Stiles DK, Zhang Z, Ge P, et al. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol. 2012;233:463\u201371.","journal-title":"Exp Neurol."},{"key":"307_CR32","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1038\/mtna.2015.20","volume":"4","author":"R Grondin","year":"2015","unstructured":"Grondin R, Ge P, Chen Q, et al. Onset time and durability of Huntingtin suppression in rhesus putamen after direct infusion of antihuntingtin siRNA. Mol Ther Nucleic Acids. 2015;4:e245.","journal-title":"Mol Ther Nucleic Acids."},{"key":"307_CR33","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86:890\u20137.","journal-title":"Neurology."},{"key":"307_CR34","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388:3017\u201326.","journal-title":"Lancet."},{"key":"307_CR35","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron. 2012;74:1031\u201344.","journal-title":"Neuron."},{"key":"307_CR36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JHD-130057","volume":"2","author":"LM Stanek","year":"2013","unstructured":"Stanek LM, Yang W, Angus S, et al. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease. J Huntingtons Dis. 2013;2:217\u201328.","journal-title":"J Huntingtons Dis."},{"key":"307_CR37","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.neuron.2012.06.001","volume":"74","author":"XH Lu","year":"2012","unstructured":"Lu XH, Yang XW. \"Huntingtin holiday\": progress toward an antisense therapy for Huntington's disease. Neuron. 2012;74:964\u20136.","journal-title":"Neuron."},{"key":"307_CR38","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.nbd.2007.11.003","volume":"29","author":"EM Denovan-Wright","year":"2008","unstructured":"Denovan-Wright EM, Rodriguez-Lebron E, Lewin AS, Mandel RJ. Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo. Neurobiol Dis. 2008;29:446\u201355.","journal-title":"Neurobiol Dis."},{"key":"307_CR39","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.bbrc.2006.01.057","volume":"341","author":"H Hayashita-Kinoh","year":"2006","unstructured":"Hayashita-Kinoh H, Yamada M, Yokota T, Mizuno Y, Mochizuki H. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem Biophys Res Commun. 2006;341:1088\u201395.","journal-title":"Biochem Biophys Res Commun."},{"key":"307_CR40","first-page":"947147","volume":"2012","author":"M Ben Aissa","year":"2012","unstructured":"Ben Aissa M, April MC, Bergeron LJ, Perreault JP, Levesque G. Silencing of amyloid precursor protein expression using a new engineered delta ribozyme. Int J Alzheimers Dis. 2012;2012:947147.","journal-title":"Int J Alzheimers Dis."},{"key":"307_CR41","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/1531-8249(199909)46:3<366::AID-ANA12>3.0.CO;2-D","volume":"46","author":"L Yen","year":"1999","unstructured":"Yen L, Strittmatter SM, Kalb RG. Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA. Ann Neurol. 1999;46:366\u201373.","journal-title":"Ann Neurol."},{"key":"307_CR42","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/mds.26007","volume":"29","author":"EJ Wild","year":"2014","unstructured":"Wild EJ, Tabrizi SJ. Targets for future clinical trials in Huntington's disease: what's in the pipeline? Mov Disord. 2014;29:1434\u201345.","journal-title":"Mov Disord."},{"key":"307_CR43","doi-asserted-by":"crossref","first-page":"E3136","DOI":"10.1073\/pnas.1206506109","volume":"109","author":"M Garriga-Canut","year":"2012","unstructured":"Garriga-Canut M, Agust\u00edn-Pav\u00f3n C, Herrmann F, et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6\/2 mice. Proc Natl Acad Sci U S A. 2012;109:E3136\u201345.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"307_CR44","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","volume":"31","author":"T Gaj","year":"2013","unstructured":"Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31:397\u2013405.","journal-title":"Trends Biotechnol."},{"key":"307_CR45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm.3793","volume":"21","author":"DB Cox","year":"2015","unstructured":"Cox DB, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med. 2015;21:121\u201331.","journal-title":"Nat Med."},{"key":"307_CR46","first-page":"4566","volume":"25","author":"JW Shin","year":"2016","unstructured":"Shin JW, Kim KH, Chao MJ, et al. Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR\/Cas9. Hum Mol Genet. 2016;25:4566\u201376.","journal-title":"Hum Mol Genet."},{"key":"307_CR47","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fnmol.2014.00076","volume":"7","author":"G Murlidharan","year":"2014","unstructured":"Murlidharan G, Samulski RJ, Asokan A. Biology of adeno-associated viral vectors in the central nervous system. Front Mol Neurosci. 2014;7:76.","journal-title":"Front Mol Neurosci."},{"key":"307_CR48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/B978-0-12-800149-3.00002-0","volume":"87","author":"B Kantor","year":"2014","unstructured":"Kantor B, McCown T, Leone P, Gray SJ. Clinical applications involving CNS gene transfer. Adv Genet. 2014;87:71\u2013124.","journal-title":"Adv Genet."},{"key":"307_CR49","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","volume":"14","author":"Z Wu","year":"2006","unstructured":"Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther. 2006;14:316\u201327.","journal-title":"Mol Ther."},{"key":"307_CR50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","volume":"24","author":"V Louis Jeune","year":"2013","unstructured":"Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods. 2013;24:59\u201367.","journal-title":"Hum Gene Ther Methods."},{"key":"307_CR51","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cmet.2011.02.013","volume":"13","author":"S Hult","year":"2011","unstructured":"Hult S, Soylu R, Bj\u00f6rklund T, et al. Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. Cell Metab. 2011;13:428\u201339.","journal-title":"Cell Metab."},{"key":"307_CR52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27:59\u201365.","journal-title":"Nat Biotechnol."},{"key":"307_CR53","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/mt.2013.289","volume":"22","author":"BD Dufour","year":"2014","unstructured":"Dufour BD, Smith CA, Clark RL, Walker TR, McBride JL. Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice. Mol Ther. 2014;22:797\u2013810.","journal-title":"Mol Ther."},{"key":"307_CR54","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nbt.3440","volume":"34","author":"BE Deverman","year":"2016","unstructured":"Deverman BE, Pravdo PL, Simpson BP, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol. 2016;34:204\u20139.","journal-title":"Nat Biotechnol."},{"key":"307_CR55","first-page":"e85311","volume":"1","author":"DA Wolf","year":"2016","unstructured":"Wolf DA, Hesterman JY, Sullivan JM, et al. Dynamic dual-isotope molecular imaging elucidates principles for optimizing intrathecal drug delivery. JCI Insight. 2016;1:e85311.","journal-title":"JCI Insight."},{"key":"307_CR56","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","volume":"113","author":"SM Hammond","year":"2016","unstructured":"Hammond SM, Hazell G, Shabanpoor F, et al. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci U S A. 2016;113:10962\u20137.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"307_CR57","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrd3010","volume":"9","author":"AL Jackson","year":"2010","unstructured":"Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010;9:57\u201367.","journal-title":"Nat Rev Drug Discov."},{"key":"307_CR58","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/ncb1038","volume":"5","author":"CA Sledz","year":"2003","unstructured":"Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol. 2003;5:834\u20139.","journal-title":"Nat Cell Biol."},{"key":"307_CR59","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jmb.2005.03.013","volume":"348","author":"M Sioud","year":"2005","unstructured":"Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol. 2005;348:1079\u201390.","journal-title":"J Mol Biol."},{"key":"307_CR60","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm1191","volume":"11","author":"V Hornung","year":"2005","unstructured":"Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005;11:263\u201370.","journal-title":"Nat Med."},{"key":"307_CR61","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.4049\/jimmunol.172.11.6545","volume":"172","author":"K Karik\u00f3","year":"2004","unstructured":"Karik\u00f3 K, Bhuyan P, Capodici J, Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol. 2004;172:6545\u20139.","journal-title":"J Immunol."},{"key":"307_CR62","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/nbt0706-796","volume":"24","author":"S Barik","year":"2006","unstructured":"Barik S. RNAi in moderation. Nat Biotechnol. 2006;24:796\u20137.","journal-title":"Nat Biotechnol."},{"key":"307_CR63","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/gt.2011.10","volume":"18","author":"JN Martin","year":"2011","unstructured":"Martin JN, Wolken N, Brown T, Dauer WT, Ehrlich ME, Gonzalez-Alegre P. Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design. Gene Ther. 2011;18:666\u201373.","journal-title":"Gene Ther."},{"key":"307_CR64","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature04791","volume":"441","author":"D Grimm","year":"2006","unstructured":"Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways. Nature. 2006;441:537\u201341.","journal-title":"Nature."},{"key":"307_CR65","first-page":"434","volume":"7","author":"F Borel","year":"2011","unstructured":"Borel F, van Logtenstein R, Koornneef A, et al. In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs. J RNAi Gene Silencing. 2011;7:434\u201342.","journal-title":"J RNAi Gene Silencing."},{"key":"307_CR66","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1261\/rna.7233305","volume":"11","author":"R Yi","year":"2005","unstructured":"Yi R, Doehle BP, Qin Y, Macara IG, Cullen BR. Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. RNA. 2005;11:220\u20136.","journal-title":"RNA."},{"key":"307_CR67","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/mt.2008.231","volume":"17","author":"RL Boudreau","year":"2009","unstructured":"Boudreau RL, Martins I, Davidson BL. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther. 2009;17:169\u201375.","journal-title":"Mol Ther."},{"key":"307_CR68","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1073\/pnas.1221891110","volume":"110","author":"K Sathasivam","year":"2013","unstructured":"Sathasivam K, Neueder A, Gipson TA, et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci U S A. 2013;110:2366\u201370.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"307_CR69","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1172\/JCI83185","volume":"126","author":"L Ru\u00e9","year":"2016","unstructured":"Ru\u00e9 L, Ba\u00f1ez-Coronel M, Creus-Muncunill J, et al. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels. J Clin Invest. 2016;126:4319\u201330.","journal-title":"J Clin Invest."},{"key":"307_CR70","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.arr.2017.03.002","volume":"36","author":"B Hall","year":"2017","unstructured":"Hall B, Mak E, Cervenka S, Aigbirhio FI, Rowe JB, O'Brien JT. In vivo tau PET imaging in dementia: pathophysiology, radiotracer quantification, and a systematic review of clinical findings. Ageing Res Rev. 2017;36:50\u201363.","journal-title":"Ageing Res Rev."},{"key":"307_CR71","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrneurol.2014.232","volume":"11","author":"A Lle\u00f3","year":"2015","unstructured":"Lle\u00f3 A, Cavedo E, Parnetti L, et al. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol. 2015;11:41\u201355.","journal-title":"Nat Rev Neurol."},{"key":"307_CR72","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"Wild EJ, Boggio R, Langbehn D, et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J Clin Invest. 2015;125:1979\u201386.","journal-title":"J Clin Invest."},{"key":"307_CR73","doi-asserted-by":"crossref","unstructured":"Finkel R, Chiriboga C, Vajsar J, et al. Interim results of a phase 2 clinical study of nusinersen (ISIS-SMNRx) in patients with infantile-onset spinal muscular atrophy. American Academy of Neurology 2016 Annual Meeting. Vancouver: Vancouver Convention Centre; 2016. http:\/\/www.neurology.org\/content\/86\/16_Supplement\/P5.004 .","DOI":"10.1212\/WNL.86.16_supplement.P5.004"},{"key":"307_CR74","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10:204\u201316.","journal-title":"Nat Rev Neurol."},{"key":"307_CR75","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","volume":"8","author":"SJ Tabrizi","year":"2009","unstructured":"Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8:791\u2013801.","journal-title":"Lancet Neurol."},{"key":"307_CR76","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1474-4422(10)70276-3","volume":"10","author":"SJ Tabrizi","year":"2011","unstructured":"Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011;10:31\u201342.","journal-title":"Lancet Neurol."},{"key":"307_CR77","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","volume":"11","author":"SJ Tabrizi","year":"2012","unstructured":"Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24\u00a0month observational data. Lancet Neurol. 2012;11:42\u201353.","journal-title":"Lancet Neurol."},{"key":"307_CR78","doi-asserted-by":"crossref","unstructured":"Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013;12(7):637\u201349.","DOI":"10.1016\/S1474-4422(13)70088-7"},{"key":"307_CR79","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","volume":"81","author":"J Nasir","year":"1995","unstructured":"Nasir J, Floresco SB, O'Kusky JR, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 1995;81:811\u201323.","journal-title":"Cell."},{"key":"307_CR80","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/81593","volume":"26","author":"I Dragatsis","year":"2000","unstructured":"Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet. 2000;26:300\u20136.","journal-title":"Nat Genet."},{"key":"307_CR81","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1073\/pnas.1524575113","volume":"113","author":"G Wang","year":"2016","unstructured":"Wang G, Liu X, Gaertig MA, Li S, Li XJ. Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc Natl Acad Sci U S A. 2016;113:3359\u201364.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"307_CR82","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1021\/bi101208k","volume":"49","author":"KT Gagnon","year":"2010","unstructured":"Gagnon KT, Pendergraff HM, Deleavey GF, et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry. 2010;49:10166\u201378.","journal-title":"Biochemistry."},{"key":"307_CR83","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1016\/j.bmcl.2009.09.004","volume":"19","author":"J Hu","year":"2009","unstructured":"Hu J, Dodd DW, Hudson RH, Corey DR. Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis-o-(aminoethoxy)phenyl]pyrrolocytosine. Bioorg Med Chem Lett. 2009;19:6181\u20134.","journal-title":"Bioorg Med Chem Lett."},{"key":"307_CR84","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1749-6632.2009.04975.x","volume":"1175","author":"J Hu","year":"2009","unstructured":"Hu J, Matsui M, Corey DR. Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. Ann N Y Acad Sci. 2009;1175:24\u201331.","journal-title":"Ann N Y Acad Sci."},{"key":"307_CR85","doi-asserted-by":"crossref","first-page":"e0171127","DOI":"10.1371\/journal.pone.0171127","volume":"12","author":"NA Datson","year":"2017","unstructured":"Datson NA, Gonz\u00e1lez-Barriga A, Kourkouta E, et al. The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. PLoS One. 2017;12:e0171127.","journal-title":"PLoS One."},{"key":"307_CR86","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","volume":"217","author":"MS Lombardi","year":"2009","unstructured":"Lombardi MS, Jaspers L, Spronkmans C, et al. A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol. 2009;217:312\u20139.","journal-title":"Exp Neurol."},{"key":"307_CR87","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1089\/hum.2007.116","volume":"19","author":"PH Bilsen van","year":"2008","unstructured":"van Bilsen PH, Jaspers L, Lombardi MS, Odekerken JC, Burright EN, Kaemmerer WF. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum Gene Ther. 2008;19:710\u20139.","journal-title":"Hum Gene Ther."},{"key":"307_CR88","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","volume":"19","author":"EL Pfister","year":"2009","unstructured":"Pfister EL, Kennington L, Straubhaar J, et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol. 2009;19:774\u20138.","journal-title":"Curr Biol."},{"key":"307_CR89","doi-asserted-by":"crossref","first-page":"46740","DOI":"10.1038\/srep46740","volume":"7","author":"JRC Miller","year":"2017","unstructured":"Miller JRC, Pfister EL, Liu W, et al. Allele-selective suppression of mutant Huntingtin in primary human blood cells. Sci Rep. 2017;7:46740.","journal-title":"Sci Rep."},{"key":"307_CR90","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/mt.2014.153","volume":"22","author":"AL Southwell","year":"2014","unstructured":"Southwell AL, Skotte NH, Kordasiewicz HB, et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol Ther. 2014;22:2093\u2013106.","journal-title":"Mol Ther."},{"key":"307_CR91","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","volume":"19","author":"JB Carroll","year":"2011","unstructured":"Carroll JB, Warby SC, Southwell AL, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene\/allele-specific silencing of mutant huntingtin. Mol Ther. 2011;19:2178\u201385.","journal-title":"Mol Ther."},{"key":"307_CR92","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","volume":"41","author":"ME \u00d8stergaard","year":"2013","unstructured":"\u00d8stergaard ME, Southwell AL, Kordasiewicz H, et al. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res. 2013;41:9634\u201350.","journal-title":"Nucleic Acids Res."},{"key":"307_CR93","doi-asserted-by":"crossref","first-page":"e107434","DOI":"10.1371\/journal.pone.0107434","volume":"9","author":"NH Skotte","year":"2014","unstructured":"Skotte NH, Southwell AL, \u00d8stergaard ME, et al. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. PLoS One. 2014;9:e107434.","journal-title":"PLoS One."},{"key":"307_CR94","unstructured":"Wave Life Sciences Press Release. Wave Life Sciences Initiates Two Phase 1b\/2a Clinical Trials: PRECISION-HD1 and PRECISION-HD2 in Patients with Huntington\u2019s Disease. 2017. http:\/\/ir.wavelifesciences.com\/phoenix.zhtml?c=254233&p=irol-newsArticle&ID=2286672 ."},{"key":"307_CR95","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","volume":"116","author":"RA Smith","year":"2006","unstructured":"Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest. 2006;116:2290\u20136.","journal-title":"J Clin Invest."},{"key":"307_CR96","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamaneurol.2013.593","volume":"70","author":"L Winer","year":"2013","unstructured":"Winer L, Srinivasan D, Chun S, et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013;70:201\u20137.","journal-title":"JAMA Neurol."},{"key":"307_CR97","unstructured":"Single and Multiple Dose Study of BIIB067 in Adults with Amyotrophic Lateral Sclerosis (ALS). NCT02623699 . Clinical Trials.gov. 2015."},{"key":"307_CR98","unstructured":"Spark Therapeutics Press Release. Spark Unveils Vision of Having 10 Clinical-Stage Gene Therapy Programs by 2018, Including One Commercial and Two in Pivotal Trials. 2016. http:\/\/ir.sparktx.com\/phoenix.zhtml?c=253900&p=irol-newsArticle&ID=2128384 ."},{"key":"307_CR99","unstructured":"Biogen Press Release. New Data Show SPINRAZA\u2122 (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy. 2017. http:\/\/media.biogen.com\/press-release\/rare-and-genetic-diseases\/new-data-show-spinraza-nusinersen-significantly-reduces-risk ."},{"key":"307_CR100","unstructured":"U.S. Food and Drug Administration (FDA) Press Release. FDA approves first drug for spinal muscular atrophy. 2016. https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm534611.htm . Accessed 23 Dec 2016."},{"key":"307_CR101","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrurol.2012.104","volume":"9","author":"F O'Kelly","year":"2012","unstructured":"O'Kelly F, Marignol L, Meunier A, Lynch TH, Perry AS, Hollywood D. MicroRNAs as putative mediators of treatment response in prostate cancer. Nat Rev Urol. 2012;9:397\u2013407.","journal-title":"Nat Rev Urol."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-017-0307-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T14:39:59Z","timestamp":1719499199000},"score":1,"resource":{"primary":{"URL":"http:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-017-0307-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["307"],"URL":"https:\/\/doi.org\/10.1186\/s13195-017-0307-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]},"article-number":"82"}}